Q1 2026 Borregaard ASA Earnings Call Transcript
Key Points
- Fine Chemicals segment delivered a strong performance with a 23% increase in operating revenues compared to the same quarter last year.
- BioMaterials segment saw a 10% increase in sales volume driven by higher deliveries of speciality cellulose.
- Borregaard ASA (STU:BO4) has a highly diversified portfolio and broad customer base, providing resilience in volatile environments.
- The company expects wood costs to decrease by around 15% in the first half of 2026 compared to the first half of 2025.
- Borregaard ASA (STU:BO4) is implementing targeted measures to address cost development, which may support long-term opportunities for bio-based alternatives.
- EBITDA decreased to NOK428 million from NOK511 million in the same quarter last year.
- BioSolutions segment experienced a 9% decrease in operating revenues due to lower sales volumes of specialities.
- Higher energy costs and general cost inflation negatively impacted the financial results.
- The average price in sales currency for BioMaterials was 4% below Q1 last year, reflecting lower sales prices and a weaker product mix.
- The geopolitical situation and conflicts, particularly in the Middle East, are causing uncertainty and impacting energy, logistics, and chemical costs negatively.
Good morning, and welcome to Borregaardâs first quarter 2026 presentation. My name is Tom Erik FossâJacobsen. Iâm the CEO of the company, and Iâll be joined today by our CFO, Per Bjarne Lyngstad. Together, we will take you through this agenda.
Iâll start with the key highlights for the quarter and then give an update on the market situation across our business segments. Iâll then summarize the outlook before handing over to Per Bjarne, who will walk you through the financial performance in more detail. Before we begin, just a quick reminder for those of you watching the webcast live that youâre welcome to submit your questions at any time during the presentation, and we will address them at the end of the presentation.
Letâs begin with the highlights for the first quarter. EBITDA came in at NOK428 million, compared with NOK511 million in the same quarter last year. In BioSolutions, we saw lower sales volumes within specialities compared with a very strong quarter last year. In BioMaterials, we delivered higher
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
